Xiuning Le, MD, PhD, on the Rationale for Assessing Tepotinib in Advanced NSCLC
Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.
At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Xiuning Le, MD, PhD, an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine at MD Anderson Cancer Center, about the rationale for conducting the phase 2 VISION trial (NCT02864992) in which patients with advanced non–small cell lung cancer (NSCLC) who had high MET amplifications were treated with tepotinib (Tepmetko). Patients were identified based on liquid biopsy and circulating tumor DNA (ctDNA) biomarkers.1
Transcript:
MET exon 14 in NSCLC has been established as an actionable mutation for about 2 years with 2 medications with capmatinib [Tabrecta] and tepotinib being approved for that patient population.2,3 That was great news for these patients. There’s an area of unmet need for patients with NSCLC if they have MET amplification as the driver of their tumor. This arm in the VISION study is evaluating if tepotinib, the MET exon 14 drug, can have a benefit or efficacy in this MET-amplified patient population.
In the VISION trial cohort B, we used ctDNA to identify the patient in the first step. We used the ctDNA MET amplification of 2.5 or greater, as a cut-off for patient enrollment. Once we identified those patients they were enrolled in the trial and we offered tepotinib as a treatment to evaluate the benefit of the drug in this patient cohort.
References
- Le X, Paz-Ares LG, Meerneeck JV, et al. Clinical response to tepotinib according to circulating tumor DNA biomarkers in patients with advanced NSCLC with high-level MET amplification detected by liquid biopsy. J Clin Oncol. 2022; 40(suppl 16):9121. doi: 10.1200/JCO.2022.40.16_suppl.9121
- FDA grants accelerated approval to capmatinib for metastatic non–small cell lung cancer. News Release. FDA. May 6, 2020. Accessed June 20, 2022.https://bit.ly/3HCfNiS
- FDA grants accelerated approval to tepotinib for metastatic non–small cell lung cancer. News Release. FDA. February 3, 2021. Accessed June 20, 2022. https://bit.ly/3b2YJX6
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
